Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2014, Article ID 828702, 5 pages
http://dx.doi.org/10.1155/2014/828702
Review Article

Lipid Peroxidation in Psychiatric Illness: Overview of Clinical Evidence

Department of Pharmacology, Center for Translational Medicine, Temple University School of Medicine, MERB 947, 3500 North Broad Street, Philadelphia, PA 19140, USA

Received 18 March 2014; Accepted 8 April 2014; Published 27 April 2014

Academic Editor: Kota V. Ramana

Copyright © 2014 Yash B. Joshi and Domenico Praticò. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Adibhatla and J. F. Hatcher, “Lipid oxidation and peroxidation in CNS Health and disease: from molecular mechanisms to therapeutic opportunities,” Antioxidants and Redox Signaling, vol. 12, no. 1, pp. 125–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. D. G. Smith, R. Cappai, and K. J. Barnham, “The redox chemistry of the Alzheimer's disease amyloid β peptide,” Biochimica et Biophysica Acta, vol. 1768, no. 8, pp. 1976–1990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. C. M. Spickett, I. Wiswedel, W. Siems, K. Zarkovic, and N. Zarkovic, “Advances in methods for the determination of biologically relevant lipid peroxidation products,” Free Radical Research, vol. 44, no. 10, pp. 1172–1202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. R. Wade and A. M. van Rij, “In vivo lipid peroxidation in man as measured by the respiratory excretion of ethane, pentane, and other low-molecular-weight hydrocarbons,” Analytical Biochemistry, vol. 150, no. 1, pp. 1–7, 1985. View at Google Scholar · View at Scopus
  5. M. Toda and A. Abi-Dargham, “Dopamine hypothesis of schizophrenia: making sense of it all,” Current Psychiatry Reports, vol. 9, no. 4, pp. 329–336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Hoffer, H. Osmond, and J. Smythies, “Schizophrenial a new approach. II. Result of a year's research,” The Journal of Mental Science, vol. 100, no. 418, pp. 29–45, 1954. View at Google Scholar
  7. X. Y. Zhang, Y. L. Tan, L. Y. Cao et al., “Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics,” Schizophrenia Research, vol. 81, no. 2-3, pp. 291–300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Y. Zhang, D. F. Zhou, L. Y. Cao, P. Y. Zhang, and G. Y. Wu, “Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms,” Psychiatry Research, vol. 117, no. 1, pp. 85–88, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Mukherjee, S. P. Mahadik, R. Scheffer, E. E. Correnti, and H. Kelkar, “Impaired antioxidant defense at the onset of psychosis,” Schizophrenia Research, vol. 19, no. 1, pp. 19–26, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. P. K. Ranjekar, A. Hinge, M. V. Hegde et al., “Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients,” Psychiatry Research, vol. 121, no. 2, pp. 109–122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Y. Zhang, D. C. Chen, M. H. Xiu et al., “Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val Polymorphism in patients with schizophrenia and normal controls,” Schizophrenia Bulletin, vol. 40, no. 3, pp. 592–601, 2014. View at Publisher · View at Google Scholar
  12. N. Srivastava, M. K. Barthwal, P. K. Dalal et al., “Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients,” Psychopharmacology, vol. 158, no. 2, pp. 140–145, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Kartalci, A. B. Karabulut, A. C. Ozcan, E. Porgali, and S. Unal, “Acute and chronic effects of electroconvulsive treatment on oxidative parameters in schizophrenia patients,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 7, pp. 1689–1694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Herken, E. Uz, H. Özyurt, S. Söǧüt, O. Virit, and Ö. Akyol, “Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia,” Molecular Psychiatry, vol. 6, no. 1, pp. 66–73, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Phillips, M. Sabas, and J. Greenberg, “Increased pentane and carbon disulfide in the breath of patients with schizophrenia,” Journal of Clinical Pathology, vol. 46, no. 9, pp. 861–864, 1993. View at Google Scholar · View at Scopus
  16. R. G. McCreadie, E. MacDonald, D. Wiles, G. Campbell, and J. R. Paterson, “The Nithsdale schizophrenia surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects,” British Journal of Psychiatry, vol. 167, pp. 610–617, 1995. View at Google Scholar · View at Scopus
  17. S. P. Mahadik, S. Mukherjee, R. Scheffer, E. E. Correnti, and J. S. Mahadik, “Elevated plasma lipid peroxides at the onset of nonaffective psychosis,” Biological Psychiatry, vol. 43, no. 9, pp. 674–679, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Dietrich-Muszalska and B. Olas, “Isoprostenes as indicators of oxidative stress in schizophrenia,” World Journal of Biological Psychiatry, vol. 10, no. 1, pp. 27–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Fusar-Poli and G. Berger, “Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies,” Journal of Clinical Psychopharmacology, vol. 32, no. 2, pp. 179–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. G. P. Amminger, M. R. Schäfer, K. Papageorgiou et al., “Long-chain ω-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial,” Archives of General Psychiatry, vol. 67, no. 2, pp. 146–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Soares-Weiser, N. Maayan, and J. McGrath, “Vitamin E for neuroleptic-induced tardive dyskinesia,” Cochrane Database of Systematic Reviews, vol. 16, no. 2, Article ID CD000209, 2011. View at Google Scholar · View at Scopus
  22. G. N. Dakhale, S. D. Khanzode, S. S. Khanzode, and A. Saoji, “Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia,” Psychopharmacology, vol. 182, no. 4, pp. 494–498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Berk, D. Copolov, O. Dean et al., “N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial,” Biological Psychiatry, vol. 64, no. 5, pp. 361–368, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. K. Yao, R. Reddy, L. G. McElhinny, and D. P. van Kammen, “Effects of haloperidol on antioxidant defense system enzymes in schizophrenia,” Journal of Psychiatric Research, vol. 32, no. 6, pp. 385–391, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Sarandol, S. Kirli, C. Akkaya, A. Altin, M. Demirci, and E. Sarandol, “Oxidative-antioxidantive systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 21, no. 5, pp. 550–552, 2007. View at Google Scholar
  26. O. Virit, A. Altindag, M. Yumru et al., “A defect in the antioxidant defense system in schizophrenia,” Neuropsychobiology, vol. 60, no. 2, pp. 87–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Andreazza, M. Kauer-Sant'Anna, B. N. Frey et al., “Oxidative stress markers in bipolar disorder: a meta-analysis,” Journal of Affective Disorders, vol. 111, no. 2-3, pp. 135–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Kunz, C. S. Gama, A. C. Andreazza et al., “Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 7, pp. 1677–1681, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. C. Andreazza, J. F. Wang, F. Salmasi, L. Shao, and L. T. Young, “Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder,” Journal of Neurochemistry, vol. 127, no. 4, pp. 552–561, 2013. View at Google Scholar
  30. H. K. Kim, A. C. Andreazza, P. Y. Yeung, C. Isaacs-Trepanier, and L. T. Young, “Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia,” Journal of Psychiatry & Neuroscience, vol. 39, no. 1, pp. 130–155, 2014. View at Google Scholar
  31. L. E. Cudney, R. B. Sassi, G. A. Behr et al., “Alterations in circadian rhythms are associated with increased lipid peroxidation in females with bipolar disorder,” The International Journal of Neuropsychopharmacology, vol. 17, pp. 1–8, 2014. View at Google Scholar
  32. R. T. de Sousa, C. A. Zarate Jr., M. V. Zanetti et al., “Oxidative stress in early stage bipolar disorder and the association with response to lithium,” Journal of Psychiatric Research, vol. 50, pp. 36–41, 2014. View at Google Scholar
  33. R. Machado-Vieira, A. C. Andreazza, C. I. Viale et al., “Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects,” Neuroscience Letters, vol. 421, no. 1, pp. 33–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. U. Banerjee, A. Dasgupta, J. K. Rout, and O. P. Singh, “Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 37, no. 1, pp. 56–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. van Melle, P. de Jonge, T. A. Spijkerman et al., “Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis,” Psychosomatic Medicine, vol. 66, no. 6, pp. 814–822, 2004. View at Google Scholar
  36. R. Rugulies, “Depression as a predictor for coronary heart disease: a review and meta-analysis,” The American Journal of Preventive Medicine, vol. 23, no. 1, pp. 51–61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Dimopoulos, C. Piperi, V. Psarra, R. W. Lea, and A. Kalofoutis, “Increased plasma levels of 8-iso-PGF2α and IL-6 in an elderly population with depression,” Psychiatry Research, vol. 161, no. 1, pp. 59–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Yager, M. J. Forlenza, and G. E. Miller, “Depression and oxidative damage to lipids,” Psychoneuroendocrinology, vol. 35, no. 9, pp. 1356–1362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Milaneschi, M. Cesari, E. M. Simonsick et al., “Health ABC study,” PLoS ONE, vol. 8, no. 6, Article ID e65406, 2013. View at Google Scholar
  40. C. Stefanescu and A. Ciobica, “The relevance of oxidative stress status in first episode and recurrent depression,” Journal of Affective Disorders, vol. 143, no. 1–3, pp. 34–38, 2012. View at Google Scholar
  41. P. Gałecki, J. Szemraj, M. Bieńkiewicz, A. Florkowski, and E. Gałecka, “Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment,” Pharmacological Reports, vol. 61, no. 3, pp. 436–447, 2009. View at Google Scholar · View at Scopus
  42. M. Bulut, S. Selek, Y. Bez et al., “Lipid peroxidation markers in adult attention deficit hyperactivity disorder: new findings for oxidative stress,” Journal of Psychiatric Research, vol. 209, no. 3, pp. 638–642, 2013. View at Google Scholar
  43. M. Kawatani, H. Tsukahara, and M. Mayumi, “Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers,” Redox Report, vol. 16, no. 1, pp. 45–46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Chakraborty, O. P. Singh, A. Dasgupta, N. Mandal, and H. N. Das, “Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 2, pp. 363–366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Bulut, S. Selek, Y. Bez et al., “Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder,” Journal of Affective Disorders, vol. 150, no. 3, pp. 829–833, 2013. View at Google Scholar
  46. H. Herken, O. Akyol, H. R. Yilmaz et al., “Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment,” Human Psychopharmacology, vol. 21, no. 1, pp. 53–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Tezcan, M. Atmaca, M. Kuloglu, and B. Ustundag, “Free radicals in patients with post-traumatic stress disorder,” European Archives of Psychiatry and Clinical Neuroscience, vol. 253, no. 2, pp. 89–91, 2003. View at Google Scholar · View at Scopus
  48. S. Rose, S. Melnyk, O. Pavliv et al., “Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain,” Translational Psychiatry, vol. 10, Article ID 2e134, 2012. View at Google Scholar
  49. F. Gu, V. Chauhan, and A. Chauhan, “Impaired synthesis and antioxidant defense of glutathione in the cerebellum of autistic subjects: alterations in the activities and protein expression of glutathione-related enzymes,” Free Radical Biology and Medicine, vol. 65, pp. 488–496, 2013. View at Google Scholar
  50. A. Chauhan, T. Audhya, and V. Chauhan, “Brain region-specific glutathione redox imbalance in autism,” Neurochemical Research, vol. 37, no. 8, pp. 1681–1689, 2012. View at Publisher · View at Google Scholar · View at Scopus